In this report, we present 2 challenging cases of IR-sclerosing cholangitis induced by triplet therapy with anti–programmed cell death ligand 1 (PD-L1) antibody, atezolizumab, and BRAF/MEK inhibitors, vemurafenib, and cobimetinib, which were complicated by pyogenic liver abscesses with bacteremia. This evidence concerns the gene MAP2K7 and sclerosing cholangitis.